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Congenital disorders of glycosylation (CDG) are a rapidly growing 
family of genetic diseases first reported in 1980 (11). They are caused 
by deficient glycosylation of glycoconjugates, such as N-linked glyco-
proteins, O-linked glycoproteinsand glycolipids. Some 60 CDG are 
actually known. Phosphoglucomutase 1 deficiency, first reported in 
1963 (11), has only recently been identified as a CDG with a  remarkably 
broad clinical presentation (5, 8, 12, 13). We report on another patient 
with this CDG.
A 19-months-old girl was admitted for evaluation of feeding difficul-
ties and recurrent hypoglycemia that occurred almost every month. 
She was the third child of consanguineous healthy parents. There was 
no family history of similar symptoms. She showed a short stature, 
prominent forehead, small face, depressed nasal bridge, unilateral-me-
dian cleft palate/bifid uvula and hepatomegaly 5 cm below the costal 
margin. Her weight was 7.1 kg (SDS: -3), height was 66 cm (SDS: -3.97). 
Psychomotor development and neurological examination were normal. 
There was epiphora due to lacrimal duct obstruction. Routine  laboratory 
investigations showed normal blood count, routine urine analysis and 
serum creatinine, total lipids, total LDL- and HDL-cholesterol, ammo-
nia, creatine phosphokinase, acylcarnitines, amino acids, thyroid hor-
mones, biotinidase activity and urine organic acids and sugar chroma-
tography. Serum transaminases were increased [AST: 291U/L, ALT: 
109U/L (nl: 0-40)]. Ultrasonographic examination showed enlarged 
liver size with normal echogenity. Echocardiography and brain (in-
cluding hypophysis) magnetic resonance imaging were normal. Dur-
ing follow-up hypoinsulinemic hypoglycemia (39 mg/dl) was detected 
with increased serum cortisol, adrenocorticotropic hormone, growth 
hormone, and normal metabolic screening tests (urine glucose and or-
ganic acids, and serum lactic acid, ammonia, bicarbonate, amino acids 
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and acylcarnitine levels. Serum insulin like growth factor 1 (IGF1) was 
low 16.15 ng/ml (nl: 55-110), but showed a normal response to growth 
hormone. Insulin like growth factor binding protein 3 (IGFBP3) was 
578 ng/ml (nl: 2450-3500). Growth hormone therapy was nevertheless 
started but hypoglycemia attacks continued and therefore this therapy 
was stopped. Serum thyroxine binding globuline was low [5 µcg/ml 
(29-54)]. Partial thromboplastin time was 41.8 (nl: 18-28) and pro-
thrombin time was 19.3 seconds (nl: 10-14) factor X 45 % (50-150), 
factor VII 15.8 % (50-150), FXI 15 % (50-150), antithrombin III 10 % 
(80-120), protein C 5 %(70-130), and protein S 8 % (65-140). On fol-
low-up, cardiomyopathy developed and serum was found increased.
Serum transferrin IEF showed a type 2 pattern. On MALDI-TOF anal-
ysis of serum transferin there was an aglycan and a monoglycan trans-
ferin species besides the normal diglycan transferin. On the basis of 
these results and clinical features, mutation analysis of the PGM1 gene 
was performed by direct sequencing of this 11 exons. A homozygous 
mutation was found: c.551delT (p.F184Sfs*9) and the parents were 
heterozygous for this mutation.
Phosphoglucomutase (PGM) comprises three isoenzymes with differ-
ent tissue distribution (PGM1, PGM2 and PGM3). PGM1 is expressed 
ubiquitously and accounts for 80-90 % of the total PGM activity in 
most tissues (4, 7). It catalyses the bidirectional interconversion of glu-
cose 1-phosphate and glucose 6-phosphate, and is thus on the cross-
road between glycolysis/glucose production and glycogen metabolism/
UDP-galactose synthesis.
PGM1 deficiency has first been reported half a century ago (11). Since 
then a few patients have been described including, in 2009, an adult 
with exercise-induced muscle cramps, episodic rhabdomyolysis, and 
muscular glycogen storage (‘glycogenesis XIV’) (5, 8, 12, 13). Only in 
2012, the full clinical presentation of PGM1 deficiency was recognized 
comprising bifid uvula/cleft palate, hepatophy with decreased coagula-
tion factors, growth retardation (with normal or increased growth hor-
mone levels), myopathy, dilated cardiomyopathy, hypoglycemia, and, 
less frequently, low serum TSH, ACTH and hypogonadotrophic hypo-
gonadism (5). The absence of neurological symptoms can be explained 
by the presence of PGM2 (3) and phosphomannomutase 1 (6) in brain. 
Moreover, at the same time PGM1 deficiency was identified as a gly-
cosylation disorder with, on the one hand, a type 2 pattern on serum 
TfIEF, pointing to a glycan remodeling defect (Golgi defect) and, on 
the other hand, a loss of complete glycans on mass spectrometry of 
intact Tf. The latter points to a glycan assembly defect (ER/pre-ER 
defect). Using the current CDG nomenclature (2) this disease should 
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be called PGM1-CDG. This dual glycosylation defect (CDG-I/II) was 
only reported in galactosemia (9). In both disorders there is an accumu-
lation of galactose 1-phosphate, probably inhibiting (by competion ?) 
the galactosylation of glycoproteins in the Golgi apparatus, while in 
PGM1-CDG there is shortage of the galactose donor UDP-galactose. 
Galactose administration should be beneficial to these patients. Re-
cently a paper, which has been published by Tegtmeyer et al., include 
phenotypic features of patients diagnosed PGM-1 CDG. In this report 
has been mentioned that, supplementation with galactose leads to bio-
chemical improvement in patients (10). 
In conclusion, PGM1-CDG broadens the already very broad phenotyp-
ic spectrum of CDG.
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